Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare hereditary disease characterized by a high skin susceptibility, formation of bubbles, erosions, chronic lesions, chronic systemic inflammation. The use of mesenchymal stem/stromal cells (MSCs) isolated from different sources can be considered as one of the RDEB treatment methods. MSCs are an ideal candidate for treating a wide range of serious diseases due to the simplicity of their isolation and reproduction, the ability to differentiate into multiple cell lines, the ability to neovasculogenesis, as well as in consequence of the pronounced paracrine effect through the production of anti-inflammatory, immunomodulating, antiapoptotic, antifibrotic and anabolic factors, that leads to damaged tissues’ recovery. At the same time, MSCs have a low immunogenicity that allows to use allogenic MSCs (without the need for aggressive patient’s conditioning as in the case of allogenic transplantation of bone marrow cells), that is especially relevant due to the RDEB nature associated with systemic inflammation. This therapy can significantly decrease the disease activity and improve the life quality of patients with RDEB by reducing inflammatory processes in the body and relieving persistent and highly disturbing symptoms — itching and pain. The article summarizes the mechanisms by which MSCs contribute to healing skin lesions, systemic anti-inflammatory effect in the treatment of patients with RDEB. The results of pre-clinical and clinical studies have been also discussed.

This publication has 59 references indexed in Scilit: